1,3,5-triazepan-2,6-diones as structurally diverse and conformationally constrained dipeptide mimetics: Identification of malaria liver stage inhibitors from a small pilot library

Chemistry - A European Journal

Volumn 12, Issue 33, 2006, Pages 8498-8512

  Lena, Gersande ^a   Lallemand, Eliette ^b   Gruner, Anne Charlotte ^b   Boeglin, Joel ^a   Roussel, Solveig ^a   Schaffner, Arnaud Pierre ^a   Aubry, André ^c   Franetich, Jean François ^d   Mazier, Dominique ^d   Landau, Irène ^e   Briand, Jean Paul ^a   Didierjean, Claude ^c   Rénia, Laurent ^b   Guichard, Gilles ^a  

^a INSTITUT DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

^b INSTITUT COCHIN   (France)

^c Nancy University CNRS   (France)

^d INSERM   (France)

^e MUSÉUM NATIONAL D'HISTOIRE NATURELLE   (France)

Author keywords

Heterocycles; Molecular diversity; Peptides; Peptidomimetics; Solid phase synthesis

Indexed keywords

AMINO ACIDS; BIOMIMETIC MATERIALS; CONFORMATIONS; MOLECULAR STRUCTURE; SYNTHESIS (CHEMICAL); X RAY DIFFRACTION;

HETEROCYCLES; MOLECULAR DIVERSITY; PEPTIDOMIMETICS; SOLID-PHASE SYNTHESIS;

KETONES;

DIPEPTIDE; ENZYME INHIBITOR; HETEROCYCLIC COMPOUND; PEPTIDE LIBRARY;

ARTICLE; CHEMISTRY; COMBINATORIAL CHEMISTRY; CONFORMATION; LIVER; MALARIA; METHODOLOGY; MOLECULAR MIMICRY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PARASITOLOGY; PATHOLOGY; PILOT STUDY; SYNTHESIS; X RAY DIFFRACTION;

COMBINATORIAL CHEMISTRY TECHNIQUES; DIPEPTIDES; ENZYME INHIBITORS; HETEROCYCLIC COMPOUNDS; LIVER; MAGNETIC RESONANCE SPECTROSCOPY; MALARIA; MOLECULAR CONFORMATION; MOLECULAR MIMICRY; PEPTIDE LIBRARY; PILOT PROJECTS; X-RAY DIFFRACTION;

EID: 33751347858     PISSN: 09476539     EISSN: 15213765     Source Type: Journal    
DOI: 10.1002/chem.200600560     Document Type: Article

References (91)

1. D. S. Tan, Nat. Chem. Biol. 2005, 1, 74-84;
2. S. L. Schreiber, Science 2000, 287, 1964-1969.
3. D. A. Horton, G. T. Bourne, M. L. Smythe, Chem. Rev. 2003, 103, 893-930.
4. For a selection of recent examples see: a) O. Müller, E. Gourzoulidou, M. Carpintero, I. -M. Karaguni, A. Langerak, C. Herrmann, T. Möröy, L. Klein-Hitpaß, H. Waldmann, Angew. Chem. 2004, 116, 456-460;
5. Angew. Chem. Int. Ed. 2004, 43, 450-454;
6. b) L. T. Vassilev, B. T. Vu, B. Graves, D. Carvajal, E. Podlaski, Z. Filipovic, N. Kong, U. Kammlott, C. Lukacs, C. Klein, N. Fotouhi, E. A. Liu, Science 2004, 303, 844-848;
7. c) F. G. Kuruvilla, A. F. Shamji, S. M. Sternson, P. J. Hergenrother, S. L. Schreiber. Nature 2002, 416, 653-657.
8. For reviews see: a) P. M. Fischer, J. Pept. Sci. 2003, 9, 9-35;
9. b) D. T. Witiak, Y. Wei, Prog. Drug Res. 1990, 35, 249-363;
10. c) M. J. O. Anteunis, Bull. Soc. Chim. Belg. 1978, 87, 627-650.
11. a) Demethoxyfumitremorgin C and tryprostatins: C.B. Cui, H. Kakeya, H. Osada, J. Antibiot. 1996, 49, 534-540;
12. b) Brevianamides: R. M. Williams, R.J. Cox, Acc. Chem. Res. 2003, 36, 127-139;
13. c) Roquefortine C: D. J. Richard, B. Schiavi, M. M. Joullie, Proc. Natl. Acad. Sci. USA 2004, 101, 11971-11976;
14. d) Rosstratins: R. X. Tan, P. R. Jensen, P. G. Williams, W. Fenical, J. Nat. Prod. 2004, 67, 1374-1382;
15. e) Vertihemiptellides: M. Isaka, S. Palasarn, P. Rachtawee, S. Vimuttipong, P. Kongsaeree, Org. Lett. 2005, 7, 2257-2260.
16. Selected examples of biologically active DKPs: a) Oxytocin antagonists: A. D. Borthwick, D. E. Davies, A. -M. Exall, D. G. Livermore, S. L. Sollis, F. Nerozzi, M. J. Allen, M. Perren, S. S. Shabbir, P. M. Woollard, P.G. Wyatt, J. Med. Chem. 2005, 48, 6956-6969;
17. b) tubulin polymerizing agents with antitumour activity: B. Nicholson. G. K. Lloyd, B. R. Miller, M. A. Palladino, Y. Kiso, Y. Hayashi, S. T. Neuteboom, Anti-cancer Drug 2006, 7, 25-31;
18. c) neuroprotective activity: A. I. Faden, V. A. Movsesyan, S. M. Knoblach, F. Ahmed, I. Cernak, Neuropharmacology 2005, 49, 410-424;
19. d) Inhibitor of plasminogen activator inhibitor (PAI)-1 activity: T. D. Brooks, S.W. Wang, N. Brunner, P. A. Charlton, Anti-cancer Drugs 2004, 15, 37-44;
20. e) tryptase inhibitors: M. del Fresno, D. Fernandez-Forner, M. Miralpeix, V. Segarra, H. Ryder, M. Royo, F. Albericio, Bioorg. Med. Chem. Lett. 2005, 15, 1659-1664.
21. For a recent review on the synthesis of DKPs see: C. J. Dinsmore. D. C. Beshore, Tetrahedron 2002, 58, 3297-3312.
22. For use of Ugi reactions see: S. L. Sollis, J. Org. Chem. 2005, 70, 4735-4740.
23. S. Cho, G. Keum, S. B. Kang, S. Y. Han, Y. Kim, Mol. Diversity 2003, 6. 283-286.
24. Cyclic N-acyliminium ions derived from peptide aldehydes are powerful intermediates that can undergo intramolecular attack by a range of nucleophiles including amide backbone NH and side chain functional groups (for example, hydroxyl, sulfhydryl, amide, amide groups, and carbon-based π-nucleophiles) to generate bicyclic scaffolds with ring structure diversity. For general solid-phase synthesis approaches see; a) T. Vojkovsky, A. Weichsel, M. Patek, J. Org. Chem. 1998, 63, 3162-3163;
25. b) T. E. Nielsen, M. Meldal, J. Org. Chem. 2004, 69, 3765-3773;
26. c) J. G. Lewis, P.A. Bartlett, J. Comb. Chem. 2003, 5, 278-284.
27. P. Johannesson, G. Lindeberg, W. Tong, A. Gogoll, A. Karlen, A. Hallberg, J. Med. Chem. 1999, 42, 601-608;
28. d) M. Eguchi, M. S. Lee, H. Nakanishi, M. Stasiak, S. Lovell, M. Kahn, J. Am. Chem. Soc. 1999, 121, 12204-12205;
29. e) T.E. Nielsen, S. Le Quement, M. Meldal, Org. Lett. 2005, 7, 581-584.
30. 3THF have been proposed as templates for the elaboration of various heterocyclic scaffolds, a) J. M. Ostresh, C. C. Schoner, V. T. Hamashin, A. Nefzi, J. P. Meyer, R. A. Houghten, J. Org. Chem., 1998, 63, 8622-8623;
31. b) A. Nefzi, J. M. Ostresh, J. Yu, R. A. Houghten, J. Org. Chem. 2004, 69, 3603-3609, and references therein;
32. c) A. Nefzi, R.T. Santos, J. Org. Chem. 2005, 70, 9622-9625;
33. d) C. E. Hoesl, J. M. Ostresh, R. A. Houghten, A. Nefzi, J. Comb. Chem. 2006, 8, 127-131.
34. G. Evindar, R. A. Batey, Org. Lett. 2003, 5, 1201-1204
35. a) 1,4-Diazepan-2,5-diones: J. C. D. Müller-Hartwieg, K. G. Akyel. J. Zimmermann, J. Pept. Sci. 2003, 9, 187-199;
36. O. El Mahdi, J. P. Lavergne, J. Martinez, P. Viallefont, E. M. Essassi, C. Riche, Eur. J. Org. Chem. 2000, 251-255;
37. b) 1,2,5-triazepan-3,6-diones: M. M. Lenman, S. L. Ingham, D. Gani, Chem. Commun. 1996, 85-87;
38. M. M. Lenman, A. Lewis, D. Gani, J. Chem. Soc. Perkin Trans. 1 1997, 2297-2311.
39. a) Containing a 1,3-diazepan-2-one skeleton; P. Y. Lam, P. K. Jadhav, C. J. Eyermann, C. N. Hodge, Y. Ru, L. T. Bacheler, J. L. Meek, M. J. Otto, M. M. Rayner, Y. N. Wong, C. H. Chang, P. C. Wever, D. A. Jackson, T. R. Sharpe, S. Erickson-Vitanen, Science 1994, 263, 380-384;
40. b) containing a 1,2,4-triazepan-3-one skeleton: H. L. Sham, C. Zhao, K. D. Stewart, D. A. Betebenner, S. Lin, C. H. Park, X. -P. Kong, W. Jr., Rosenbrook, T. Herrin, D. Madigan, S. Vasavanonda, N. Lyons, A. Molla, A. Saldivar, K. C. Marsh, E. McDonald, N. E. Wideburg, J. F. Denissen, T. Robins, D. J. Kempf, J. J. Plattner, D. W. Norbeck, J. Med. Chem. 1996, 39, 392-397.
41. J. D. Rodgers, A. J. Cocuzza, D.M. Bilder, US 6 204 262, 2001.
42. Chem. Abstr. 2001 134, 237502.
43. R. A. Galemmo Jr, T. P. Maduskuie, C. Dominguez, K. A. Rossi, R. M. Knabb, R. R. Wexlcr, P. F. Stouten, Bioorg. Med. Chem. Lett. 1998, 8, 2705-2710.
44. A. Bonnefoy, C. Dupuis-Hamelin, V. Steier, C. Delachaume, C. Seys, T. Stachyra, M. Fairley, M. Guitton, M. Lampilas, J. Antimicrob. Chemother. 2004, 54, 410-417.
45. S. F. Martin, B. C. Follows, P. J. Hergenrother, C. L. Franklin, J. Org. Chem. 2000, 65, 4509-4514.
46. R. Nishizawa, Y. Takaoka, H. Habashita, S. Shibayama, M. Kokubo, WO 2004092169, 2004;
47. [Chem. Abstr. 2004 141, 395 591].
48. To our knowledge, seven triazepandione systems out of 16 possible isomers have been reported so far in the literature, a) 1,2,4-Triazepan-3,5-dione; A. Hasnaoui, J. -P. Lavergne, P. Viallefont, J. Heterocycl. Chem. 1978, 15, 71-75;
49. b) 1,2,4-triazepan-3,7-dione: C.N. Hodge, C.H. Fernandez, P. K. Jadhav, P. Y. Lam, WO 9422840, 1994;
50. [Chem. Abs. 1994, 123, 33104];
51. c) 1,2,5-triazepan-3,4-dione: A.M.M. El-Saghier, A.A. Maihub, H. Al-Shirayda, Synth. Commun. 1997, 27, 2433-2444;
52. d) 1,2,5-triazepan-3,6-dione: see reference [11b];
53. e) 1,2,5-triazepan-3,7-dione: C. Hassal, G. Lawon, S. Radshaw, EP 172552, 1986;
54. [Chem. Abs. 1986, 105, 115 100];
55. f) 1,3,5-triazepan-2,4-dione: H. Sawanishi, S. Wakusawa, R. Murakami, H. Muramatsu, H. Suzuki, A. Takashima, T. Aizawa, K. -I. Miyamoto, J. Med. Chem. 1995, 38, 5066-5070;
56. T. Yu, J. M. Ostresh, R. A. Houghten, Org. Lett. 2001, 3, 2797-2799;
57. g) 1,3,5-triazepan-2,7-dione: K. Hirota, K. Maruhashi, N. Kitamura, T. Asao, S. Senda, J. Chem. Soc. Perkin Trans, 1 1984, 1719-1723.
58. We use a nomenclature based on the amino acid three letter code to describe 1,3,5-triazepan-2,6-diones. Accordingly, heterocycles prepared from the dipeptide sequence Boc-Xaa-Xbb-OH will be denoted cyclo(Xaa-gXbb-CO). g = gem, refers to the 2-alkyl gem-diamino-derivative of the corresponding amino acid according to the nomenclature proposed by Goodman. M. Chorev, M. Goodman, Acc. Chem. Res. 1993, 26, 266-273.
59. V. Semetey, C. Didierjean, J. -P. Briand, A. Aubry, G. Guichard. Angew. Chem. 2002, 114, 1975-1978
60. : Angew. Chem. Int. Ed. 2002, 41, 1895-1898.
61. a) G. Guichard, V. Semetey, C. Didierjean, A. Aubry, J. P. Briand, M. Rodriguez, J. Org. Chem. 1999, 64, 8702-8705;
62. b) V. Semetey, D. Rognan, C. Hemmerlin, C. Didierjean, A. -P. Schaffner, A. Gimenez Giner, A. Aubry, J. -P. Briand, M. Marraud, G. Guichard, Org. Lett. 2001, 3, 3843-3846.
63. 2O and filtration.
64. J. J. Weidner, J. J. Parlow D. L. Flynn, Tetrahedron Lett. 1999, 40, 239-242.
65. Chapters 3.2 and 3.3 in C. C. Tzschucke, C. Markert, W. Bannwarth, S. Roller, A. Hebel, R. Haag, Angew. Chem. 2002, 114, 4136-4173;
66. Angew. Chem. Int. Ed. 2002, 41, 3964-4000.
67. M. Adamczyk, J. R. Fishpaugh, P. G. Mattingly, Tetrahedron Lett. 1999, 40, 463-466.
68. T. Shioiri, K. Ninomiya, S. Yamada, J. Am. Chem. Soc. 1972, 94, 6203-6205.
69. a) D. A. Nugiel, K. Jacobs, L. Cornelius, C. -H. Chang, P. K. Jadhav, E. R. Holler, R. M. Klabe, L. T. Bacheler, B. Cordova, S. Garber, C. Reid, K. A. Logue, L. J. Gorey-Feret, G. N. Lam, S. Erickson-Viitanen, S. P. Seitz, J. Med. Chem. 1997, 40, 1465-1474;
70. b) J. Hultén, N. M. Bonham, U. Nillroth, T. Hansson, G. Zucarello, A. Bouzide, J. Aqvist, J., B. Classon, U. H. Danielson, A. Karlen, I. Kvarnström, B. Samuelsson, A. Hallberg, J. Med. Chem. 1997, 40, 885-897.
71. P. Y. S. Lam, Y. Ru, P. K. Jadhav, P. E. Aldrich, G. V. DeLucca, C. J. Eyermann, C. -H. Chang, G. Emett, E. R. Holler, W. F. Danedker, L. Li, P. N. Confalone, R. J. McHugh, Q. Han, R. Li, J. A. Markwalder, S. P. Seitz, T. R. Sharpe, L. T. Bacheler, M. M. Rayner, R. M. Klabe, L. Shum, D. L. Winslow, D. M. Kornhauser, D. A. Jackson, S. Erickson-Viitanen, C. N. Hodge, J. Med. Chem. 1996, 39, 3514-3525.
72. W. W. Wilkerson, S. Dax, W. W. Cheatham, J. Med. Chem. 1997, 40, 4079-4088.
73. B. R. P. Stone, G. D. Harris, R. O. Cann, T. E. Smyser and P. N. Confalone, Tetrahedron Lett. 1998, 39, 6127-6130.
74. N. A. Meanwell, S. Y. Sit, J. Gao, H. S. Wong, Q. Gao, D. R. St. Laurent, N. Balasubramanian, J. Org. Chem. 1995, 60, 1565-1582.
75. 3 in organic synthesis see: B. E. Blass, Tetrahedron 2002, 58, 9301-9320.
76. Quantitative removal of protecting groups in 9 and 11 by treatment with TFA afforded an additional set of triazepandiones with free carboxylic side chains (12 and 13, respectively).
77. CCDC-283640 to -28346 contain the crystal structures of 4J, 4k, 4l, 4o, 4s, 9i, and 11c. These data can be obtained free of charge from the Cambridge Crystallographic Data Centre via www.ccdc.cam. ac.uk/data_request/cif.
78. For a structure report of 4h see: G. Lena, E. Wenger, G. Guichard, C. Didierjean, Acta Crystallogr. Sect. E 2006, 62, O518-O520.
79. During the crystallographic refinements, all H atoms were placed in calculated positions and refined by using a riding model, with C-H distances 0.93-0.98 Å and an N-H distance of 0.86 Å. G. M. Shel-drick, SHELXL-97, University of Göttingen, Göttingen, Germany, 1997.
80. See Table IV in: I. L, Karle, H. C. Ottenheym, B. Witkop, J. Am. Chem. Soc. 1974, 96, 539-543 and references therein.
81. J. C. MacDonald, G. M. Whitesides, Chem. Rev. 1994, 94, 2383-2420.
82. I. L. Karle, J. Am. Chem. Soc. 1972, 94, 81-84.
83. 2)8 dimers and can eventually pack into H-bonded molecular tapes. In the solid state, cyclo(L-Phe-gSar-CO) (4 a) was found to form H-bonded helicoidal molecular tapes with P chirality that self-assemble to give hollow tubular structures. A. P. Schaffner, G. Lena, S. Roussel, A. Aubry, J.-P. Briand, C. Didierjean, G. Guichard, Chem. Commun., DOI: 10.1039/B604747E.
84. For recent reviews on antimalarial drugs see: a) J. Wiesner, R. Ortmann, H. Jomaa, M. Schlitzer, Angew. Chem. 2003, 115, 5432-5451;
85. Angew. Chem. Int. Ed., 2003, 42, 5274-5293;
86. b) A. -C. Labbé, M. R. Loufty, K. C. Kain, Curr. Inf. Dis. Rep. 2001, 3, 68-76.
87. -1, see Supporting Information).
88. D. Mazier, R. L. Beaudoin, S. Mellouk, P. Druilhe, B. Texier, J. Trosper, F. Miltgen, I. Landau, C. Paul, O. Brandicourt, C. Guguen-guillouzo, P. Langlois, M. Gentilini, Science 1985, 227, 440-442.
89. T. R. Mosmann, J. Immunol. Methods 1983, 65, 55-63.
90. L. Renia, D. M. Mattei, J. Goma, S. Pied, P. Dubois, F. Miltgen, A. K. Nussler, H. Matile, F. Menegaux, M. Gentilini, D. Mazier, Eur. J. Immunol. 1990, 20, 1445-1449.
91. M. Tsuji, D. M. Mattei, R. S. Nussenzweig, D. Eichinger, F. Zavala, Parasitol, Res. 1994, 80, 16-21.